Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial (vol 8, e000891, 2020)

被引：0
|
作者：
Motzer, R. J.
Escudier, B.
McDermott, D. F.
机构：
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2021年 / 9卷 / 05期
关键词：
D O I：
10.1136/jitc-2020-000891corr1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
    Motzer, Robert J.
    Escudier, Bernard
    McDermott, David F.
    Frontera, Osvaldo Aren
    Melichar, Bohuslav
    Powles, Thomas
    Donskov, Frede
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Hammers, Hans J.
    George, Saby
    Gruenwald, Viktor
    Porta, Camillo
    Neiman, Victoria
    Ravaud, Alain
    Choueiri, Toni K.
    Rini, Brian, I
    Salman, Pamela
    Kollmannsberger, Christian K.
    Tykodi, Scott S.
    Grimm, Marc-Oliver
    Gurney, Howard
    Leibowitz-Amit, Raya
    Geertsen, Poul F.
    Amin, Asim
    Tomita, Yoshihiko
    McHenry, M. Brent
    Saggi, Shruti Shally
    Tannir, Nizar M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [2] Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Tannir, Nizar M.
    McDermott, David F.
    Escudier, Bernard
    Hammers, Hans J.
    Aren, Osvaldo Rudy
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Neiman, Victoria
    George, Saby
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    Grimm, Marc-Oliver
    Amin, Asim
    Tykodi, Scott S.
    Tomita, Yoshihiko
    Rini, Brian I.
    McHenry, M. Brent
    Saggi, Shruti Shally
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [3] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
    Cella, David
    Gruenwald, Viktor
    Escudier, Bernard
    Hammers, Hans J.
    George, Saby
    Nathan, Paul
    Grimm, Marc-Oliver
    Rini, Brian, I
    Doan, Justin
    Ivanescu, Cristina
    Paty, Jean
    Mekan, Sabeen
    Motzer, Robert J.
    LANCET ONCOLOGY, 2019, 20 (02): : 297 - 310
  • [4] Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
    Tomita, Yoshihiko
    Kondo, Tsunenori
    Kimura, Go
    Inoue, Takamitsu
    Wakumoto, Yoshiaki
    Yao, Masahiro
    Sugiyama, Takayuki
    Oya, Mototsugu
    Fujii, Yasuhisa
    Obara, Wataru
    Motzer, Robert J.
    Uemura, Hirotsugu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (01) : 12 - 19
  • [5] Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
    Motzer, Robert
    Rini, Brian, I
    McDermott, David F.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael A.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Neiman, Victoria
    Bracarda, Sergio
    Tykodi, Scott S.
    Barthelemy, Philippe
    Leibowitz-Amit, Raya
    Plimack, Elizabeth R.
    Oosting, Sjoukje F.
    Redman, Bruce
    Melichar, Bohusiav
    Powles, Thomas
    Nathan, Paul
    Oudard, Stephan
    Pook, David
    Choueiri, Toni K.
    Donskov, Frede
    Grimm, Marc-Oliver
    Gurney, Howard
    Heng, Daniel Y. C.
    Kollmannsberger, Christian K.
    Harrison, Michael R.
    Tamita, Yoshihiko
    Duran, Ignacio
    Gruenwold, Viktor
    McHenry, M. Brent
    Mekan, Sabeen
    Tannir, Nizar M.
    LANCET ONCOLOGY, 2019, 20 (10): : 1370 - 1385
  • [6] Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab plus ipilimumab (N plus I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
    Tannir, Nizar M.
    Frontera, Osvaldo Aren
    Hammers, Hans J.
    Carducci, Michael Anthony
    McDermott, David F.
    Salman, Pamela
    Escudier, Bernard
    Beuselinck, Benoit
    Amin, Asim
    Porta, Camillo
    George, Saby
    Bracarda, Sergio
    Tykodi, Scott S.
    Powles, Thomas
    Rini, Brian I.
    Tomita, Yoshihiko
    McHenry, M. Brent
    Mekan, Sabeen Fatima
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Saggi, Shruti Shally
    McHenry, M. Brent
    Motzer, Robert J.
    ESMO OPEN, 2020, 5 (06)
  • [8] Long-term follow-up on overall survival and independent review of response in CheckMate 214: first-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Grimm, M. -O.
    Tannir, N.
    McDermott, D.
    Escudier, B.
    Hammers, H.
    Aren Frontera, O.
    Plimack, E.
    Barthelemy, P.
    Neiman, V.
    George, S.
    Porta, C.
    Powles, T.
    Donskov, F.
    Amin, A.
    Tykodi, S.
    Tomita, Y.
    Rini, B.
    McHenry, M. B.
    Saggi, S. S.
    Motzer, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 208 - 208
  • [9] Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: 8-year follow-up with analyses in favorable risk patients from the phase 3 CheckMate 214 trial
    Atkins, Michael B.
    Escudier, Bernard
    Mcdermott, David F.
    Burotto, Mauricio
    Choueiri, Toni K.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Porta, Camillo
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Kollmannsberger, Christian K.
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Rini, Brian, I
    Jiang, Ruiyun
    Federov, Viktor
    Lee, Chung-Wei
    Desilva, Heshani
    Tannir, Nizar M.
    Motzer, Robert J.
    ONCOLOGIST, 2024, 29 : S17 - S18
  • [10] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial (vol 20, pg 297, 2019)
    Cella, D.
    Grunwald, V
    Escudier, B.
    LANCET ONCOLOGY, 2019, 20 (06): : E293 - E293
12345